-
Apr 29, 2021 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1831.
-
Apr 15, 2021 GOVERNMENT OF CANADA AWARDS APOTEX INC. A SIGNIFICANT CONTRACT TO SUPPLY A SAFETY NET OF ADDITIONAL DEXAMETHASONE IN CANADA
-
Apr 13, 2021 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot RF0410.
-
Jun 12, 2020 Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.
-
May 26, 2020 Canada’s largest pharmaceutical manufacturer donates thousands of bottles of hand sanitizer to hospitals across Quebec
-
May 25, 2020 Toronto Company Launches Hiring Blitz During COVID-19
-
Apr 21, 2020 Canada’s Apotex Donates Two Million Dosages of Hydroxychloroquine to the Public Health Agency of Canada
-
Apr 17, 2020 Canada's Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers
-
Apr 13, 2020 Canada's Largest Pharmaceutical Company Produces Hand Sanitizer to Support the Fight Against COVID-19
-
Mar 20, 2020 Apotex Donates Hydroxychloroquine for a Clinical Study to Prevent Infection From Covid-19 With Front Line Health Care Workers
-
Feb 4, 2020 Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.
-
Dec 5, 2019 Apotex Releases New Supply of Tamoxifen into Canadian Market
-
Jun 1, 2018 Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval
-
Sep 1, 2017 VOLUNTARY NATIONWIDE RECALL: One lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex standard, 0.4MG/Metered dose due to possibility of non-spraying pump
-
Feb 9, 2017 VOLUNTARY NATIONWIDE RECALL: One lot of ALYSENA™ 28 (Levonorgestrel and Ethinyl Estradiol tablets, USP 100 mcg/20 mcg) Due to Possibility of Broken/Chipped Tablets
-
Mar 31, 2016 Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
-
Mar 24, 2016 Apotex Launches First Generic Version of Merck's Nasonex®
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.
-
Oct 5, 2026
Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.
-
Sep 29, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.